Myriad Genetics, Inc. (MYGN) Social Stream
MYRIAD GENETICS INC (MYGN) Price Targets From Analysts
Use the tables below to see what analysts covering MYRIAD GENETICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-04 | 6 | $35 | $26 | $30.6 | $18.08 | 69.25% |
| 2022-02-25 | 6 | $33 | $26 | $29.4 | $18.08 | 62.61% |
| 2022-02-28 | 6 | $32 | $24 | $28.4 | $18.08 | 57.08% |
| 2022-03-03 | 6 | $30 | $26 | $28 | $18.08 | 54.87% |
| 2022-04-04 | 6 | $30 | $24.001 | $27.2 | $18.08 | 50.44% |
| 2022-04-20 | 6 | $29 | $24.001 | $26.8 | $18.08 | 48.23% |
| 2022-05-06 | 6 | $29 | $24.001 | $26.6 | $18.08 | 47.12% |
| 2022-05-09 | 6 | $27 | $20 | $24.2 | $18.08 | 33.85% |
| 2022-06-03 | 6 | $27 | $20 | $23.2 | $18.08 | 28.32% |
| 2022-07-15 | 6 | $26 | $20 | $22.8 | $18.08 | 26.11% |
| 2022-08-13 | 6 | $32 | $20 | $25.6 | $18.08 | 41.59% |
| 2022-09-17 | 6 | $32 | $20 | $26.4 | $18.08 | 46.02% |
| 2022-10-06 | 7 | $32 | $20 | $25.666 | $18.08 | 41.96% |
| 2022-10-17 | 6 | $32 | $20 | $25.666 | $18.08 | 41.96% |
| 2022-11-01 | 6 | $32 | $20 | $25.166 | $18.08 | 39.19% |
| 2022-11-02 | 7 | $27 | $20 | $23.833 | $18.08 | 31.82% |
| 2022-11-03 | 7 | $25 | $18 | $21.166 | $18.08 | 17.07% |
| 2022-12-12 | 7 | $25 | $18 | $20.833 | $18.08 | 15.23% |
| 2023-01-06 | 7 | $25 | $18 | $20.166 | $18.08 | 11.54% |
| 2023-01-26 | 7 | $25 | $18 | $20.857 | $18.08 | 15.36% |
| 2023-03-01 | 7 | $25 | $17 | $20.428 | $18.08 | 12.99% |
| 2023-03-03 | 7 | $27 | $17 | $20.857 | $18.08 | 15.36% |
| 2023-03-06 | 7 | $27 | $18 | $21.857 | $18.08 | 20.89% |
| 2023-04-03 | 7 | $27 | $18 | $22 | $18.08 | 21.68% |
| 2023-04-18 | 7 | $27 | $18 | $22.428 | $18.08 | 24.05% |
| 2023-04-21 | 7 | $30 | $18 | $23.142 | $18.08 | 28% |
| 2023-05-05 | 8 | $30 | $18 | $23 | $18.08 | 27.21% |
| 2023-06-06 | 8 | $30 | $18 | $23.875 | $18.08 | 32.05% |
| 2023-07-05 | 8 | $30 | $18.001 | $23.5 | $18.08 | 29.98% |
| 2023-07-24 | 8 | $30 | $18.001 | $23.875 | $18.08 | 32.05% |
| 2023-08-03 | 8 | $30 | $18.001 | $24.25 | $18.08 | 34.13% |
| 2023-08-04 | 8 | $28 | $18.001 | $23.687 | $18.08 | 31.01% |
| 2023-08-08 | 8 | $28 | $17 | $23.312 | $18.08 | 28.94% |
| 2023-09-20 | 8 | $28 | $17 | $22.937 | $18.08 | 26.86% |
| 2023-10-18 | 8 | $28 | $17 | $22.187 | $18.08 | 22.72% |
| 2023-11-07 | 8 | $28 | $17 | $21.812 | $18.08 | 20.64% |
| 2023-11-08 | 8 | $28 | $14 | $21.687 | $18.08 | 19.95% |
| 2023-12-01 | 8 | $28 | $14 | $21.437 | $18.08 | 18.57% |
| 2023-12-20 | 9 | $28 | $14 | $21.611 | $18.08 | 19.53% |
The Trend in the Analyst Price Target
MYGN's average price target has moved up $1.02 over the prior 45 weeks.
MYGN reports an average of 11.59% for its upside potential over the past 48 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-01 | 7 | 25 | 17 | 20.428 | 21.42 | -4.63% |
| 2023-09-20 | 8 | 28 | 17 | 22.937 | 17.00 | 34.92% |
| 2023-10-18 | 8 | 28 | 17 | 22.187 | 15.06 | 47.32% |
| 2023-11-07 | 8 | 28 | 17 | 21.812 | 17.76 | 22.82% |
| 2023-11-08 | 8 | 28 | 14 | 21.687 | 17.89 | 21.22% |
MYGN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 1 | 1 | 5 | 1 | 1 | 9 |
The Trend in the Broker Recommendations
Over the past 35 weeks, MYGN's average broker recommendation rating improved by 0.29.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MYGN as an investment opportunity.
- In terms of how MYRIAD GENETICS INC fares relative to all US stocks, note that its average analyst price target is greater than 1277.25% of that group.
- In terms of how MYRIAD GENETICS INC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -1005.15% of that group.
- In the context of Pharmaceutical Products stocks, MYRIAD GENETICS INC's upside potential (average analyst target price relative to current price) is greater than 1251.09% of them.
- MYRIAD GENETICS INC's number of analysts covering the stock is greater than 1841.51% of stocks in the mid market cap category.
Stocks similar to MYRIAD GENETICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are NEOG, EVO, and MOR.
View All Top Stocks by Price Target
Is MYGN a Buy, Hold or Sell? See the POWR Ratings now!